The American Journal of Managed Care2d
AI's Role in Oncology: Supporting, Not Replacing, Health Care Providers
In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he ...
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson
Can-Fite’s data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium Can-Fite enrolls patients for its ...
BioSpace12d
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson
About Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address ...
precisionmedicineonline1d
African, Asian Ancestry Patients Less Likely to Be Eligible for New Precision Oncology Drugs
A new study found that fewer African and Asian patients had clinically actionable alterations for lung, breast, and colorectal cancer.
Yahoo Finance13d
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address Oncology and Inflammatory diseases ...
manilatimes3d
Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025
The poster is titled Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 ...
Pharmabiz2d
US FDA accepts and grants priority review status to Dizal’s sunvozertinib NDA in relapsed or refractory NSCLC patients with EGFR exon20ins
US FDA accepts and grants priority review status to Dizal’s sunvozertinib NDA in relapsed or refractory NSCLC patients with EGFR exon20ins: Shanghai Thursday, January 9, 2025, 1 ...
Pharmabiz3d
US FDA grants breakthrough therapy designation to GSK’s B7-H3-targeted ADC, GSK’227 to treat relapsed or refractory osteosarcoma
US FDA grants breakthrough therapy designation to GSK’s B7-H3-targeted ADC, GSK’227 to treat relapsed or refractory osteosarcoma: London, UK Wednesday, January 8, 2025, 10:00 ...
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector
Despite significant advances in oncology research, challenges remain as the American Cancer Society recently highlighted a sharp rise in early-onset colorectal cancer cases globally, signaling a ...